Soleno Therapeutics, Inc. Common Stock
SLNOStock
$0.00+2548.62%52W
Market Cap$2.76B
P/E132.26x
Div yield—
Beta3.97
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)6.07%
Price vs S&P 500 (4W)-4.30%
VGM Score72.85
Market Capitalization$2.76B
P/E Ratio (Annual)132.26x
Earnings Surprise History
Q1 260.59est. 0.69
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.32
2.69
2.69
2.69
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLNOSoleno Therapeutics, Inc. Common Stock | D | A | A | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Soleno Therapeutics is a biopharmaceutical company developing novel treatments for rare diseases. Its lead product candidate, DCCR (Diazoxide Choline), is a proprietary extended-release formulation designed to activate KATP channels in the brain, pancreas, and fat tissue. The company targets underserved patient populations with significant unmet medical needs.